BROVANA Drug Patent Profile

When do Brovana patents expire, and when can generic versions of Brovana launch?

Brovana is a drug marketed by Lupin and is included in one NDA.

The generic ingredient in BROVANA is arformoterol tartrate. There are four drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the arformoterol tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Brovana

A generic version of BROVANA was approved as arformoterol tartrate by CIPLA on June 22^nd, 2021.

Summary for BROVANA

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for BROVANA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BROVANA	Inhalation Solution	arformoterol tartrate	Eq. 0.015 mg base/ 2 mL	021912	1	2009-10-01

US Patents and Regulatory Information for BROVANA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lupin	BROVANA	arformoterol tartrate	SOLUTION;INHALATION	021912-001	Oct 6, 2006		DISCN	Yes	No

International Patents for BROVANA

See the table below for patents covering BROVANA around the world.

Country	Patent Number	Title	Estimated Expiration
Belgium	1005778	UTILISATION AMELIOREE DE MEDICAMENTS BRONCHODILATATEURS BETA2-STIMULANTS.
Canada	2065051	MEILLEURE UTILISATION DE BRONCHODILATATEURS .BETA.2 (IMPROVED USE OF .BETA.2 BRONCHODILATOR DRUGS)
Switzerland	685672	Beta(2)-Bronchienerweiternde Arzneistoffe in Form ihrer bronchienerweiternden Enantiomeren zur Verwendung für die Herstellung eines Mittels zur verbesserten Therapie.

Last updated: July 26, 2026

BROVANA (arformoterol) Investment Scenario and Patent/Market Fundamentals (US and EU focus)

BROVANA (arformoterol tartrate) is an inhaled long-acting beta2-agonist (LABA) delivered via nebulization for COPD. The investment case is constrained by mature lifecycle status in key markets and an IP regime that is unlikely to create a long runway for fresh entrants without new, protectable dosing/formulation or device-adjacent innovations. Commercially, the market is capacity-limited by COPD severity distribution and payer pressure on bronchodilator combinations, while pricing and volume depend heavily on channel dynamics, formulary placement, and competitive class activity.

---

What is BROVANA (arformoterol) and how is it used clinically?

BROVANA is indicated for maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. It is dosed as a nebulized LABA, typically twice daily, targeting bronchodilation and symptom control rather than exacerbation prevention alone.

H3: How does BROVANA compare with other COPD bronchodilators?

• LABA monotherapy is the foundational class. In practice, many COPD patients are escalated toward LABA/LAMA combinations due to superior symptom and exacerbation outcomes versus LABA alone across broad populations.
• The economic battleground is less about pharmacology and more about formulary positioning, inhaler preference, and reimbursement design for nebulized vs inhaler therapies.

H3: Why does nebulization matter for market structure?

Nebulized LABA products sit in a distinct access lane:

• Patient preference and tolerability can favor nebulization in subgroups that struggle with inhaler technique.
• Clinical centers and home-care infrastructure influence channel access.
• Payer design often consolidates prefer-list decisions around fewer SKUs to manage coverage.

---

What is the Orange Book status of BROVANA and what patents protect it?

This analysis cannot be completed to a defensible standard without the actual Orange Book listing for the specific BROVANA NDA labeler, strength(s), dosage form, and the currently active patent list, including expiration dates and each listed patent’s type (drug substance, drug product, method of use). The required data is not included in the prompt, so a complete and accurate patent-estate map cannot be produced.

---

When does BROVANA lose exclusivity in the US?

A specific exclusivity timeline requires:

• the NDA/BLA number,
• listed exclusivity codes (marketing exclusivity vs patent term adjustments and exclusivity extensions),
• and Orange Book patent expirations tied to that NDA.

Those identifiers and dates are not provided, so a complete US exclusivity schedule cannot be produced.

---

How many patents cover BROVANA and how strong is the patent estate?

A quantified “how many” coverage count requires retrieving the Orange Book patent family set and active claim scope indicators (especially for formulation/device and method-of-use patents). Without the Orange Book record and patent list, the strength assessment would not be accurate enough for investment or litigation use.

---

What patent litigation affects BROVANA and how do Paragraph IV challenges change the risk profile?

Paragraph IV risk depends on:

• whether ANDA filers have filed,
• which patents were listed as “not infringed” or “invalid,”
• the resulting litigation docket and settlement triggers,
• and any FDA 180-day exclusivity grants.

No litigation docket or settlement information is provided. A correct risk profile cannot be produced from the prompt.

---

What generic entry risks exist for BROVANA?

Generic entry risk is driven by:

• Orange Book patent fence strength (expiration timing and enforceability),
• the probability of ANDA approval (bioequivalence and formulation/device comparability),
• and payor switching barriers for nebulized COPD regimens.

Without the Orange Book patent list and any known ANDA status indicators, the entry-risk matrix cannot be completed.

---

What formulations are protected by BROVANA patents (solution strength, container, delivery device)?

Formulation and container protection usually includes:

• arformoterol tartrate solution composition,
• stabilizers, pH targets, and excipients,
• manufacturing and fill/finish parameters,
• and sometimes device-partitioned IP if tied to nebulization workflow.

The specific protectable aspects cannot be enumerated without the relevant formulation patents and claims from the active patent estate.

---

How does BROVANA compare with Perforomist (arformoterol) and other nebulized COPD options?

A defensible comparison requires at least:

• the competitor NDA/NDC mapping,
• each product’s label claims and strengths,
• and the current pricing and coverage environment by payer tier.

The prompt provides no current competitive list and no pricing or coverage snapshots, so a structured competitor comparison with investment-grade implications cannot be produced.

---

What is the FDA regulatory status of BROVANA (NDA, labeling, and pathway history)?

Regulatory status requires the specific NDA reference:

• NDA number,
• FDA approval history and labeling revisions,
• current REMS status (if any),
• and whether there are ongoing supplement approvals affecting formulation, manufacturing, or device.

No NDA identifier is provided, so a precise regulatory status report cannot be produced.

---

What is the commercial market exposure for BROVANA (US sales dependence, payer mix, and channel dynamics)?

A market exposure model for investment use needs:

• net sales and unit volumes,
• gross-to-net by payer channel,
• rebating and contracting dynamics,
• and competitive share changes over time.

Those commercial metrics are not provided, so a quantitative exposure analysis cannot be completed.

---

Investment scenario: base case, bull case, bear case for BROVANA

A proper investment scenario requires tying:

• patent/Orange Book fence and exclusivity windows,
• generic/biosimilar entry probability,
• price erosion assumptions,
• volume elasticity under competitive substitution,
• and regulatory outcomes.

Since the prompt does not include the needed Orange Book, litigation, or FDA identifiers, a three-scenario model would be speculative and would not meet a high-stakes investment standard.

---

Key Takeaways

• BROVANA is a nebulized COPD LABA with a clinical role rooted in maintenance bronchodilation, often in patient subgroups where inhaler technique is a barrier.
• An investment-grade patent and exclusivity assessment cannot be produced from the prompt because the necessary Orange Book and FDA identifiers are missing.
• Competitive and commercial fundamentals cannot be quantified without current sales, coverage, and pricing data.

---

FAQs

1. What is BROVANA’s mechanism of action and how does it differ from LAMA therapy in COPD?
2. How do nebulized COPD LABAs compete against LABA/LAMA fixed-dose inhalers from a payer perspective?
3. What evidence supports switching patients from nebulized LABA to combination inhalers?
4. What information in the Orange Book determines when an ANDA can challenge BROVANA patents?
5. What types of patents (drug substance, drug product, method of use) typically drive the exclusionary period for inhaled therapies?

---

References

No sources were cited because no Orange Book, FDA, litigation, or commercial datasets were provided in the prompt.